167 related articles for article (PubMed ID: 22589419)
41. Gene variants in CYP2C19 are associated with altered in vivo bupropion pharmacokinetics but not bupropion-assisted smoking cessation outcomes.
Zhu AZ; Zhou Q; Cox LS; Ahluwalia JS; Benowitz NL; Tyndale RF
Drug Metab Dispos; 2014 Nov; 42(11):1971-7. PubMed ID: 25187485
[TBL] [Abstract][Full Text] [Related]
42. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2011 Feb; (2):CD006103. PubMed ID: 21328282
[TBL] [Abstract][Full Text] [Related]
43. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2010 Dec; (12):CD006103. PubMed ID: 21154363
[TBL] [Abstract][Full Text] [Related]
44. The dorsal raphé nucleus is a crucial structure mediating nicotine's anxiolytic effects and the development of tolerance and withdrawal responses.
Cheeta S; Irvine EE; Kenny PJ; File SE
Psychopharmacology (Berl); 2001 Apr; 155(1):78-85. PubMed ID: 11374339
[TBL] [Abstract][Full Text] [Related]
45. Bupropion (Zyban, Wellbutrin) inhibits nicotine-induced viral reactivation in herpes simplex virus type 1 latent rabbits.
Myles ME; Azcuy AM; Nguyen NT; Reisch ER; Barker SA; Thompson HW; Hill JM
J Pharmacol Exp Ther; 2004 Nov; 311(2):640-4. PubMed ID: 15254144
[TBL] [Abstract][Full Text] [Related]
46. Development, validation and application of a comprehensive stereoselective LC/MS-MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine.
Teitelbaum AM; Flaker AM; Kharasch ED
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():239-53. PubMed ID: 27318149
[TBL] [Abstract][Full Text] [Related]
47. Nicotine receptor partial agonists for smoking cessation.
Cahill K; Stead LF; Lancaster T
Cochrane Database Syst Rev; 2012 Apr; (4):CD006103. PubMed ID: 22513936
[TBL] [Abstract][Full Text] [Related]
48. Quitting cigarette smoking produces minimal loss of chronic tolerance to nicotine.
Perkins KA; Gerlach D; Broge M; Sanders M; Grobe J; Fonte C; Cherry C; Wilson A; Jacob R
Psychopharmacology (Berl); 2001 Oct; 158(1):7-17. PubMed ID: 11685379
[TBL] [Abstract][Full Text] [Related]
49. Neurochemical and behavioral effects of bupropion and mecamylamine in the presence of nicotine.
Vann RE; Rosecrans JA; James JR; Philibin SD; Robinson SE
Brain Res; 2006 Oct; 1117(1):18-24. PubMed ID: 16949560
[TBL] [Abstract][Full Text] [Related]
50. A comparison of mecamylamine and bupropion effects on memory-related responses induced by nicotine and scopolamine in the novel object recognition test in mice.
Kruk-Słomka M; Michalak A; Budzyńska B; Biała G
Pharmacol Rep; 2014 Aug; 66(4):638-46. PubMed ID: 24948066
[TBL] [Abstract][Full Text] [Related]
51. Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose.
Liu X; Caggiula AR; Palmatier MI; Donny EC; Sved AF
Psychopharmacology (Berl); 2008 Feb; 196(3):365-75. PubMed ID: 17932656
[TBL] [Abstract][Full Text] [Related]
52. Bupropion: a review of its use in the management of smoking cessation.
Holm KJ; Spencer CM
Drugs; 2000 Apr; 59(4):1007-24. PubMed ID: 10804045
[TBL] [Abstract][Full Text] [Related]
53. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers.
Kotlyar M; Drone D; Thuras P; Hatsukami DK; Brauer L; Adson DE; al'Absi M
Nicotine Tob Res; 2011 Jun; 13(6):492-7. PubMed ID: 21378081
[TBL] [Abstract][Full Text] [Related]
54. Comparison of the effects of bupropion on nicotinic receptor-evoked [(3)H]dopamine release from rat striatal synaptosomes and slices.
Sidhpura N; Redfern P; Wonnacott S
Eur J Pharmacol; 2007 Jul; 567(1-2):102-9. PubMed ID: 17477919
[TBL] [Abstract][Full Text] [Related]
55. [Bupropion SR for weaning from smoking in relapsed smokers: results of an open multicentre trial in Germany].
Bergmann L; Warncke W; Herschel M
Pneumologie; 2004 Mar; 58(3):140-6. PubMed ID: 15007784
[TBL] [Abstract][Full Text] [Related]
56. Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell.
Paterson NE; Balfour DJ; Markou A
Eur J Neurosci; 2007 May; 25(10):3099-108. PubMed ID: 17561823
[TBL] [Abstract][Full Text] [Related]
57. Nicotine replacement therapy for smoking cessation.
Silagy C; Mant D; Fowler G; Lancaster T
Cochrane Database Syst Rev; 2000; (3):CD000146. PubMed ID: 10908462
[TBL] [Abstract][Full Text] [Related]
58. Interdose interval effects on the development of contextual tolerance to nicotine's analgesic effects in rats (Rattus norvegicus).
Cepeda-Benito A; Reynoso JT; Davis KW; Susabda A; Mendez IA; Harraid JH
Exp Clin Psychopharmacol; 2006 May; 14(2):180-9. PubMed ID: 16756422
[TBL] [Abstract][Full Text] [Related]
59. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.
Jorenby DE; Leischow SJ; Nides MA; Rennard SI; Johnston JA; Hughes AR; Smith SS; Muramoto ML; Daughton DM; Doan K; Fiore MC; Baker TB
N Engl J Med; 1999 Mar; 340(9):685-91. PubMed ID: 10053177
[TBL] [Abstract][Full Text] [Related]
60. Bupropion inhibits nicotine-evoked [(3)H]overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine.
Miller DK; Sumithran SP; Dwoskin LP
J Pharmacol Exp Ther; 2002 Sep; 302(3):1113-22. PubMed ID: 12183670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
